Rezera Reported Positive Results for Ruvonoflast Study
The pharmaceutical company announced that an experimental weight-loss adjunct met safety and efficacy goals.
Updated on Oct. 7, 2026 in Weight Loss
Live Poll
Would you choose an experimental drug combination if it promised better control of chronic inflammation?
Rezera Inc. has released positive topline data from its Phase 2 RESOLVE-2 clinical trial. The study evaluated the safety and inflammatory effects of adding ruvonoflast to semaglutide therapy in adults with obesity.
Why it matters
The study aims to determine if ruvonoflast can offer additive benefits when paired with existing weight-loss treatments. By targeting inflammation, the company seeks to address residual health risks often associated with obesity.
The 32-week trial enrolled 82 participants who were all treated with subcutaneous semaglutide titrated to a maximum weekly dose of 2.4 mg. Researchers specifically measured additive reductions in hsCRP markers compared to monotherapy.
The players
Rezera Inc.
A Boston-based pharmaceutical company that focuses on developing treatments for metabolic and cardiovascular diseases.
The details
Participants in the randomized, multicenter study were split 1:1 to receive either oral ruvonoflast or a placebo alongside their weekly semaglutide. The company reported no new safety signals during the 32-week trial period.
Timeline
Rezera announced the RESOLVE-2 trial results on October 7, 2026.
The American Heart Association Scientific Sessions are scheduled for November 6-9, 2026.
The Big Picture
The upcoming presentation at the American Heart Association Scientific Sessions follows a standard industry practice for validating novel cardiovascular research. Rezera plans to follow this established precedent to share its findings with the broader medical community.
This development represents a potential future shift in how patients on GLP-1 therapy manage underlying inflammation. Patients should monitor future clinical updates to see if this adjunct eventually receives regulatory approval for clinical use.
The takeaway
This trial highlights the pharmaceutical industry's focus on combination therapies to manage obesity-related inflammation. Patients currently utilizing weight-loss medication should consult with their healthcare providers regarding the long-term management of inflammatory markers.
What happens next
Rezera intends to present the full findings from the RESOLVE-2 trial at the American Heart Association Scientific Sessions in Chicago, which takes place November 6-9, 2026.
Further reading
For more information on the evolving landscape of obesity medicine, visit the Weight Loss section.
Live Poll
Would you choose an experimental drug combination if it promised better control of chronic inflammation?
